Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Long-term, Extension Study to Assess the Safety of Epratuzumab Treatment in Japanese Subjects With Systemic Lupus Erythematosus

NCT01534403 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT01534403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01534403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Long-term, Extension Study to Assess the Safety of Epratuzumab Treatment in Japanese Subjects With Systemic Lupus Erythematosus
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2012
Completion date
February 28, 2015
Enrollment
17 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus